81587-18-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzyloxycarbonylamino-2-methylpropionamide is used as a building block for the production of pharmaceuticals. Its ability to protect amino groups during peptide synthesis makes it a valuable tool in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
2-Benzyloxycarbonylamino-2-methylpropionamide is used as a building block in the production of agrochemicals. Its role in protecting amino groups during peptide synthesis can contribute to the development of new pesticides, herbicides, and other agricultural chemicals.
Used in Materials Science:
2-Benzyloxycarbonylamino-2-methylpropionamide is used as a building block in materials science. Its protective properties for amino groups during peptide synthesis can be applied to create new materials with specific properties, such as improved strength, flexibility, or chemical resistance.
Used in Chemical Research:
2-Benzyloxycarbonylamino-2-methylpropionamide is used as a reagent in chemical research, particularly in the field of organic synthesis. Its ability to protect amino groups during peptide synthesis allows researchers to explore new chemical reactions and develop innovative synthetic pathways.

Upstream product

• 100134-82-5 (cyano-dimethyl-methyl)carbamic acid benzyl ester 
• 15030-72-5 Z-Aib-OH 

Downstream Products

• 77-71-4 5,5-dimethyl-imidazolidine-2,4-dione 
• 518047-98-8 [1-(N'-hydroxycarbamimidoyl)-1-methyl-ethyl]carbamic acid benzyl ester 
• 857664-99-4 methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-methoxypyrimidine-4-carboxylate 
• 518048-01-6 methyl 5-(benzoyloxy)-2-(1-{[(benzyloxy)carbonyl]amino}-1-methylethyl)-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 518048-00-5 methyl 5-(benzoyloxy)-2-(2-(benzyloxycarbonylamino)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxylate 
• 100134-82-5 (cyano-dimethyl-methyl)carbamic acid benzyl ester 
• 1401526-07-5 benzyl N-[1-methyl-1-(2-oxo-1,3,4-oxathiazol-5-yl)ethyl]carbamate 
• 1401526-09-7 methyl 3-[1-(benzyloxycarbonylamino)-1-methyl-ethyl]isothiazole-5-carboxylate 
• 1401526-08-6 methyl 3-[1-(benzyloxycarbonylamino)-1-methyl-ethyl]isothiazole-4-carboxylate 
• 16252-90-7 2-amino-2-methylpropanamide 
• 1095824-36-4 benzyl N-(2-amino-1,1-dimethyl-2-thioxo-ethyl)carbamate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

NOVEL COMPOUNDS

Compounds of the general formula (I) wherein the substituents are as defined in claim 1, are useful as fungicides.

QUINOLINE DERIVATIVES AS FUNGICIDES

Compounds of the general formula (I) wherein the substituents are as defined in claim 1, are useful as fungicides.

Hydroxyl may not be indispensable for raltegravir: Design, synthesis and SAR Studies of raltegravir derivatives as HIV-1 inhibitors

A series of raltegravir derivatives 20-42 were prepared and systematically evaluated for their anti-HIV activity. The bioassay results showed that most of the compounds possess good to excellent anti-HIV activity. Especially, compounds 25 and 35 with subpicomole IC50 values seemed to be the most potent anti-HIV agents among all of the reported synthesized compounds. These compounds may therefore be considered as new potent anti-HIV agents. The 5-hydroxyl modification of raltegravir derivatives significantly increased the anti-HIV activity, which indicates that the hydroxyl may not be indispensable for raltegravir. The introducing of acyl at 5-position of raltegravir derivatives is favorable for antiviral activity. In addition, a high-throughput cell-based assay method with pseudotyped virus stocks was developed and used to identify HIV inhibitors.

Heterocyclic Compounds Useful as RAF Kinase Inhibitors

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

COMPOUNDS USEFUL AS RAF KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

NITROGENOUS FUSED-RING DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE DERIVATIVES, AND USE THEREOF AS DRUGS

The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications or obesity, in the formula R 1 represent H, an optionally substituted alkyl group, an alkenyl group, etc.; R 2 represent H, a halogen atom or an alkyl group; R 3 and R 4 represent H, OH, a halogen atom, an optionally substituted alkyl group, etc. ; Y represents CH or N; Q represents alkylene, alkenylene, etc.; ring A represents an aryl group or a heteroaryl group; G represents a group represented by the following general formula (G-1)or(G-2) (in which E 1 represents H, F or OH; and E 2 represents H, F, a methyl group, etc.), and pharmaceutical compositions comprising the same, and pharmaceutical uses thereof.

PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents a single bond, a C1-6 alkylene group etc. ; Z represents CO or SO2; R4 and R5 represent H, an optionally substituted C1-6 alkyl group etc.; and R3, R6 and R7 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.

PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF

The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group represented by the general formula: or a group represented by the general formula: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents -RB, -CORC etc. in which RB represents an optionally substituted C1-6 alkyl group etc.; and RC represents an optionally substituted C1-6 alkyl group etc.,; R4 represents H, an optionally substituted C1-6 alkyl group etc.; and R3, R5 and R6 represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.